Share This Article:

Synthesis and Biological Evaluation of Novel Homopiperazine Derivatives as Anticancer Agents

Abstract Full-Text HTML XML Download Download as PDF (Size:1207KB) PP. 507-514
DOI: 10.4236/jct.2011.24069    4,970 Downloads   9,314 Views   Citations


In search of new anticancer agents, a series of novel 1-benzhydryl-4-(substituted phenylcarboxamide / carbothioamide)-1,4-diazepane derivatives were designed, synthesized and characterized using 1H NMR, LCMS and elemental analysis. These molecules were evaluated for their anti-cancer activity by trypan blue exclusion and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay on B-cell leukemic cell line, Reh. Carboxamide moiety containing derivatives showed good activity compared to the corresponding carbothioamide derivatives. In particular, 4-benzhydryl-N-(3-chlorophenyl)-1,4-diazepane-1-carboxamide showed good activity with IC50 value of 18 µM.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

S. Teimoori, K. Panjamurthy, K. Vinaya, D. Prasanna, S. Raghavan and K. Rangappa, "Synthesis and Biological Evaluation of Novel Homopiperazine Derivatives as Anticancer Agents," Journal of Cancer Therapy, Vol. 2 No. 4, 2011, pp. 507-514. doi: 10.4236/jct.2011.24069.


[1] C. Sawyers, “Targeted Cancer Therapy,” Nature, Vol. 432, 2004, pp. 294-297.
[2] Q. Li and W. Xu, “Novel Anticancer Targets and Drug Discovery in Post Genomic Age,” Current Medicinal Chemistry Anticancer Agents, Vol. 5, 2005, pp. 53-63.
[3] S. K. Mencher and L. G. Wang, “Promiscuous Drugs Compared to Selective Drugs,” BMC Clinical Pharmacology, Vol. 5, 2005, pp. 3-9.
[4] A. Jimeno and M. Hidalgo, “Multitargeted Therapy: Can Promiscuity Be Praised in an Era of Political Correctness?” Critical Reviews in Oncology/Hematology, Vol. 59, No. 2, 2006, pp. 150-158. doi:j.critrevonc.2006.01.005
[5] Y. Kawakami, H. Kitani, S. Yuasa, M. Abe, M. Moriwaki, M. Kagoshima, M. Terasawa and T. Tahara, “Structural Optimization of 4-(2-Chlorophenyl)-9-methyl-6H-thieno [3, 2-f]-[1,2,4]triazolo[4,3-a][1,4]diazepines as Antagonists for Platelet Activating Factor: Pharmacological Contribution of Substituents at the 2- and 6-Positions of a Condensed Ring System,” European Journal of Medicinal Chemistry, Vol. 31, No. 9, 1996, pp. 683-692. doi:0223-5234(96)85877-6
[6] K. Spencer, N. Santosh and L. Resnick, “Synthesis of the Liposidomycin Diazepanone,” Tetrahedron Letters, Vol. 33, No. 38, 1992, pp. 5485-5486. doi:S0040-4039(00)61123-1
[7] S. Kato, H. Harada, and T. Morie, “Efficient Synthesis of (6R)-6-Amino-1-methyl-4-(3-methylbenzyl)hexahydro-1H-1,4-diazepine from Methyl (2R)- and (2S)-1-Benzyloxy-carbonylaziridine-2-carboxylates,” Journal of the Chemical Society, Perkin Transactions, Vol. 1, 1997, pp. 3219-3225. doi:10.1039/a703661b
[8] Y. Hirokawa, I. Fujiwara, K. Suzuki, H. Harada, T. Yoshikawa, N. Yoshida, and S. Kato, “Synthesis and Structure-Affinity Relationships of Novel N-(1-Ethyl-4-methyl-hexahdro-1,4-diazepiN-6-yl)pyridine-3-carboxamides with Potent Serotonin 5-HT3 and Dopamine D2 Receptor Antagonistic Activity,” Journal of Medicinal Chemistry, Vol. 46, 2003, pp. 702-715. doi:10.1021/jm020270n
[9] M. P. Curtis, W. Dwight, J. Pratt, M. Cowart, T. A. Esbenshade, K. M. Kruger, G. B. Fox, J. B. Pan, T. G. Pagano, A. A. Hancock, R. Faghih and Y. Bennani, “D- Amino Acid Homopiperazine Amides: Discovery of A-320436, a Potent and Selective Non-Imidazole Histamine H3-Receptor Antagonist,” Archiv der Pharmazie, Vol. 337, No. 4, 2004, pp. 219-229. doi:10.1002/ardp.200300844
[10] C. Taillefumier, S. Thielges, et al., “Anomeric Spiroannelated 1,4-Diazepine 2,5-diones from Furano Exo-Glycals: Towards a New Class of Spironucleosides,” Tetrahedron, Vol. 60, No. 10, 2004, pp. 2213-2224.
[11] D. J. Lauffer and M. D. Mullican, “A Practical Synthesis of (S) 3-Tert-butoxycarbonylamino-2-oxo-2,3,4,5-tetrahydro-1,5-benzodiazepine-1-acetic Acid Methyl Ester as a Conformationally Restricted Dipeptido-Mimetic for Caspase-1 (ICE) Inhibitors,” Bioorganic and Medicinal Chemistry Letters, Vol. 12, No. 8, 2002, pp. 1225-1227.
[12] S. A. Lakatosh, Y. N. Luzikov and M. N. Preobrazhenskaya, “Synthesis of 6H-Pyrrolo[3’,4’:2,3][1,4]diazepino [6,7,1-hi]indole-8,10(7H,9H)-diones Using 3-Bromo-4-(indol-1-yl) Maleimide Scaffold,” Organic & Biomolecular Chemistry, Vol. 1, 2003, pp. 826-833. doi:10.1039/b211163b
[13] J. I. Levin, J. F. Dijoseph, L. M. Killar, A. Sung, T. Walter, M. A. Sharr, C. E. Roth, J. S. Skotnicki and J. D. Albright, “The Synthesis and Biological Activity of a Novel Series of Diazepine MMP Inhibitors,” Bioorganic and Medicinal Chemistry Letters, Vol. 8, No. 19, 1998, pp. 2657-2662. doi:S0960-894X(98)00473-9
[14] Y. L. Janin, A. M. Aubertin, A. Chiaroni, C. Riche, C. Monneret, E. Bisagani and D. S. Grierson, “Imidazo (1,5-G)(1,4)diazepines, TIBO Analogues Lacking the Phenyl Ring: Synthesis and Evaluation as Anti-HIV Agents,” Tetrahedron, Vol. 52, No. 48, 1996, pp. 15157-15170.
[15] N. Mibu, M. Yukawa, N. Kashige, Y. Iwase, Y. Goto, F. Miake, T. Yamaguchi, S. Ito and K. Sumoto, “Synthesis and DNA Strand Breakage Activity of Some 1,4-Diazepines,” Chemical & Pharmaceutical Bulletin, Vol. 51, No. 127, 2003, pp. 27-31. doi:10.1248/cpb.51.27
[16] D. S. Prasanna, C. V. Kavitha, K. Vinaya, S. R. Ranganatha, Sathees C. Raghavan and K. S. Rangappa, “Synthesis and Identification of a New Class of Antileukemic Agents Containing 2-(Arylcarboxamide)-(S)-6-amino-4,5, 6,7-tet-rahydrobenzo[d]thiazole,” European Journal of Medicinal Chemistry, Vol. 45, No. 11, 2010, pp. 5331-5336.
[17] D. S. Prasanna, C. V. Kavitha, B. Raghava, K. Vinaya, S. R. Ranganatha, S. C. Raghavan and K. S. Rangappa, “Synthesis and Identification of a New Class of (S)-2,6-Diamino-4,5,6,7-tetrahydrobenzo[d]thiazole Derivatives as Potent Antileukemic Agents,” Investigational New Drugs, Vol. 28, No. 4, 2010, pp. 454-465.
[18] D. S. Prasanna, C. V. Kavitha, K. Vinaya, S. R. Ranganatha, B. Raghava, Y. C. Sunil Kumar, Sathees C. Raghavan, K. S. Rangappa, “Synthesis and Antileukemic Activity of 1-((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-3-(substituted phenyl)urea Derivatives,” Bulletin of the Chemical Society of Japan, Vol. 83, No. 6, 2010, pp. 689-697. doi:10.1246/bcsj.20090318
[19] C. V. Kavitha, M. Nambiar, C. S. Ananda Kumar, B. Choudhary, K. Muniyappa, K. S. Rangappa and S. C. Raghavan, “Novel Derivatives of Spirohydantoin Induce Growth Inhibition Followed by Apoptosis in Leukemic Cells,” Biochemical Pharmacology, Vol. 77, No. 3, 2009, pp. 348-363. doi:j.bcp.2008.10.018
[20] K. K. Chiruvella, V. Kari, B. Choudhary, M. Nambiar, R. G. Ghanta and S. C. Raghavan, “Methyl Angolensate, a Natural Tetranortriterpenoid Induces Intrinsic Apoptotic Pathway in Leukemic Cells,” FEBS Letters, Vol. 582, No. 29, 2008, pp. 4066-4076.
[21] M. S. Shahabuddin, M. Nambiar, B. Choudhary, G. M. Advirao and S. C. Raghavan, “A Novel DNA Intercalator, Butylamino-pyrimido[4’,5’:4,5] selenolo(2,3-b)quinoline, Induces Cell Cycle Arrest and Apoptosis in Leukemic Cells,” Investigational New Drugs, Vol. 28, No. 1, 2010, pp. 35-48.

comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.